← Leaderboards
Mukaila A Raji
University Of Texas Med Br Galveston
$2,530,348
Attributed
$5,250,174
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,250,174 · 4
By mechanism
R01$4,845,127 · 2
P30$401,839 · 1
M01$3,208 · 1
Top collaborators
- Yong-Fang Kuo12 shared
- Huey-Ming Tzeng3 shared
Most similar at University Of Texas Med Br Galveston
Same institution · by research overlap
- Yong-Fang Kuo$6,039,433
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsPoliciesMedicareFractureFallsElderlyVariantReportingOpioid UsePhysiciansPain ManagementProviderPainSafetyChronicOperative Surgical ProceduresEffectivenessGuidelinesDoseOpioidPatternPrescription OpioidHydrocodoneHospitalization
Grant awards (14)
Annual wellness visit policy: Impact on disparities in early dementia diagnosis and quality of healthcare for Medicare beneficiaries with Alzheimer's Disease and Its Related Dementias$662,905
R01 · FY2025 · AG
Research Education Component$401,839
P30 · FY2025 · AG · contact PI
Annual wellness visit policy: Impact on disparities in early dementia diagnosis and quality of healthcare for Medicare beneficiaries with Alzheimer's Disease and Its Related Dementias$710,764
R01 · FY2024 · AG
Annual wellness visit policy: Impact on disparities in early dementia diagnosis and quality of healthcare for Medicare beneficiaries with Alzheimer's Disease and Its Related Dementias$409,906
R01 · FY2023 · AG
Effectiveness, toxicity and safety of opioid and benzodiazepine substitutes$355,500
R01 · FY2023 · DA
Effectiveness, toxicity and safety of opioid and benzodiazepine substitutes$355,500
R01 · FY2022 · DA
Effectiveness, toxicity and safety of opioid and benzodiazepine substitutes$355,500
R01 · FY2021 · DA
Effectiveness, toxicity and safety of opioid and benzodiazepine substitutes$355,500
R01 · FY2020 · DA
Pattern, Variation and Outcomes of Opioid Prescription in Older Adults$348,750
R01 · FY2019 · DA
Pattern, Variation and Outcomes of Opioid Prescription in Older Adults$348,750
R01 · FY2018 · DA
Patterns and variation of opioid use in long-stay nursing home residents with dementia$244,552
R01 · FY2018 · DA
Pattern, Variation and Outcomes of Opioid Prescription in Older Adults$348,750
R01 · FY2017 · DA
Pattern, Variation and Outcomes of Opioid Prescription in Older Adults$348,750
R01 · FY2016 · DA
S0000, SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)$3,208
M01 · FY2009 · RR · contact PI